Company profile: Endpoint Health
1.1 - Company Overview
Company description
- Provider of precision immunology solutions, including targeted therapeutics tailored to patient biology for immune-mediated diseases, companion diagnostics to personalize treatment, a precision immunology ecosystem with pharma, biotech, diagnostics providers and clinical data registries, and clinical collaborations with over 60 global health systems to develop precision therapies.
Products and services
- Companion Diagnostics: Clinically integrated diagnostic products architected to work alongside targeted therapies, delivering patient-specific guidance to personalize treatment for patients
- Precision Immunology Ecosystem: Interoperable collaborative network connecting pharma, biotech, diagnostics providers, and clinical data registries to advance precision medicine development for immune-mediated illnesses through shared datasets and coordinated clinical insights
- Targeted Therapeutics: Custom-engineered therapies developed and commercialized to match individual patient biology and clinical needs, producing precision treatments specifically for immune-mediated diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Endpoint Health
Resolvyx
HQ: United States
Website
- Description: Provider of therapeutics based on small molecule lipid mediators for the treatment of inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Resolvyx company profile →
CalciMedica
HQ: United States
Website
- Description: Provider of CRAC channel inhibitor therapies for acute and chronic inflammatory diseases, including Auxora, an IV CRAC inhibitor in development for acute pancreatitis, asparaginase-induced pancreatic toxicity, acute kidney injury, and ARDS, and oral CRAC inhibitors for conditions such as chronic pancreatitis and rheumatoid arthritis. Conducts clinical trials including CARPO, CRSPA, KOURAGE, and CARDEA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CalciMedica company profile →
180 Life Sciences
HQ: United States
Website
- Description: Provider of novel drug development focused on treating distinct inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 180 Life Sciences company profile →
BioSenic
HQ: United States
Website
- Description: Provider of therapies addressing innate immunity, inflammation, and organ/function repair, including arsenic trioxide-based treatments for autoimmune diseases and chronic graft versus host disease (ArsciCor, an oral formulation with rapid gastrointestinal solubilization and optimal bioavailability), cell therapy products for major bone defects and maxillofacial applications, and a Phase III trial of oral arsenic trioxide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioSenic company profile →
Stromedix
HQ: United States
Website
- Description: Provider of drugs targeting fibrosis, organ failure, and cancer, initially focused on chronic indications, with plans to expand into related settings such as acute organ failure and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stromedix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Endpoint Health
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Endpoint Health
2.2 - Growth funds investing in similar companies to Endpoint Health
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Endpoint Health
4.2 - Public trading comparable groups for Endpoint Health
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →